A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2

Abstract

Background No universal classification method for intrahepatic cholangiocarcinoma (IHCC) has been reported based on the embryological origin of biliary epithelial cells. The aim of this study was to classify IHCC according to protein expression levels of somatostatin receptor 2 (SSTR2) and b-cell leukemia/lymphoma 2 (Bcl2) and to elucidate the clinicopathological features of each group. Methods Fifty-two IHCC patients who underwent hepatic resection were enrolled in this study. Protein expression levels of SSTR2 and Bcl2 were examined using immunohistochemistry. Clinicopathological factors were compared between the three groups and prognostic factors were investigated. Results The patients were divided into three groups: SSTR2 positive and Bcl2 negative (p-Group H, n = 21), SSTR2 negative and Bcl2 positive (p-Group P, n = 14), and the indeterminate group (p-Group U, n = 17) for cases where SSTR2 and Bcl2 were both positive or both negative. All p-Group P cases displayed curability A or B. The 5-year survival rates of p-Group H and U patients were worse than those in p-Group P. p-Group H had higher T-factor, clinical stage, and incidence of periductal infiltration than p-Group P. Conclusions This method could be used to classify IHCC into peripheral and perihilar type by embryological expression patterns of SSTR2 and Bcl2.

Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker

“…To date, BCL2 has not been shown to play a prominent role in CCA, and little is known about PDGFRB in this context. Initial evidence has been generated thus far, as BCL2‐high iCCAs have been associated with better prognosis, lower pT category and lower frequency of periductal infiltration 73 . In vivo experiments utilizing the experimental inhibition of PDGFRB via imatinib resulted in reduced tumour growth and increased apoptosis in a rat model of CCA 74 .…”

“…Initial evidence has been generated thus far, as BCL2‐high iCCAs have been associated with better prognosis, lower pT category and lower frequency of periductal infiltration. 73 In vivo experiments utilizing the experimental inhibition of PDGFRB via imatinib resulted in reduced tumour growth and increased apoptosis in a rat model of CCA. 74 Thus, these pathways might be potential targets for iCCA since PIK3CA , a central member of the PI3K complex, ranks at position seven according to OncoIMPACT analysis, with an OIS of 36.6.…”

Progression of a persisting mesenchymal hamartoma to intrahepatic cholangiocarcinoma 24 years after the initial diagnosis: A case report

“…The expression of CK-19 in our patient indicated abnormal proliferation of bile ducts. iCCA is an adenocarcinoma arising from the intrahepatic bile ducts [ 16 ]. Loss of p53 expression implied malignant transformation.…”

Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma

“…FAP (dilution 1:250, ab207178; Abcam PLC, Cambridge, UK), SMA (dilution 1:100, ab7818; Abcam PLC), and 5-LO (dilution 1:300, ab169755; Abcam PLC) were used as the primary antibodies. The immunohistochemistry procedures were performed as previously reported [ 18 ]. Briefly, specimens were fixed in 10% formalin, embedded in paraffin, and sliced into 5 μm-thick serial sections.…”